Biosimilar Pharmaceuticals

"Biosimilar Pharmaceuticals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

BIOLOGIC PRODUCTS that are imitations but not exact replicas of innovator products.

Descriptor ID	D059451
MeSH Number(s)	D20.215.261
Concept/Terms	Biosimilar Pharmaceuticals Biosimilar Pharmaceuticals Pharmaceuticals, Biosimilar Biosimilars Biosimilars

Below are MeSH descriptors whose meaning is more general than "Biosimilar Pharmaceuticals".

Chemicals and Drugs [D]
Complex Mixtures [D20]
Biological Products [D20.215]
Biosimilar Pharmaceuticals [D20.215.261]

Below are MeSH descriptors whose meaning is related to "Biosimilar Pharmaceuticals".

Below are MeSH descriptors whose meaning is more specific than "Biosimilar Pharmaceuticals".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Biosimilar Pharmaceuticals" by people in this website by year, and whether "Biosimilar Pharmaceuticals" was a major or minor topic of these publications.

Bar chart showing 12 publications over 8 distinct years, with a maximum of 2 publications in 2017 and 2021 and 2022 and 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2015	1	0	1
2017	1	1	2
2019	1	0	1
2020	0	1	1
2021	1	1	2
2022	2	0	2
2023	2	0	2
2024	1	0	1

Below are the most recent publications written about "Biosimilar Pharmaceuticals" by people in Profiles.

Valikodath NG, Rathinavelu J, Deaner JD, Buckley M, Grewal DS. Comparison of Reference and Biosimilar Medications for Pediatric Noninfectious Uveitis. Int Ophthalmol Clin. 2024 Oct 01; 64(4):69-73.

View in: PubMed
Israilevich RN, Sharma K, Starr MR. Biosimilars for Retinal Diseases: A Review of the Literature. Int Ophthalmol Clin. 2024 Jan 01; 64(1):129-139.

View in: PubMed
Sharma A, Holz FG, Regillo CD, Freund KB, Sarraf D, Khanani AM, Baumal C, Holekamp N, Tadayoni R, Kumar N, Parachuri N, Kuppermann BD, Bandello F, Querques G, Loewenstein A, ?zdek S, Rezai K, Laurent K, Bilgic A, Lanzetta P, Zur D, Yannuzzi N, Corradetti G, Kaiser P, Hilely A, Boyer D, Rachitskaya A, Chakravarthy U, Wintergerst M, Sarao V, Parolini B, Mruthyunjaya P, Nguyen QD, Do D, Keane PA, Hassan T, Sridhar J, Eichenbaum D, Grewal D, Splitzer M. Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert Opin Biol Ther. 2023 Jul-Dec; 23(8):851-859.

View in: PubMed
Sharma A, Kumar N, Parachuri N, Regillo C, Bandello F, Kuppermann BD. Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians? Eye (Lond). 2023 07; 37(10):1953-1954.

View in: PubMed
Sharma A, Kumar N, Parachuri N, Regillo CD, Bandello F, Kuppermann BD. Retina: a unique subspecialty in the biosimilar landscape. Eye (Lond). 2022 06; 36(6):1145-1146.

View in: PubMed
Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, Cohen S, Cooper HS, Deming D, Farkas L, Garrido-Laguna I, Grem JL, Gunn A, Hecht JR, Hoffe S, Hubbard J, Hunt S, Johung KL, Kirilcuk N, Krishnamurthi S, Messersmith WA, Meyerhardt J, Miller ED, Mulcahy MF, Nurkin S, Overman MJ, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Gurski LA. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 03 02; 19(3):329-359.

View in: PubMed
Khanal O, Lenhoff AM. Developments and opportunities in continuous biopharmaceutical manufacturing. MAbs. 2021 Jan-Dec; 13(1):1903664.

View in: PubMed
Deaner JD, Srivastava SK, Hajj-Ali RA, Lowder CY, Venkat AG, Baynes K, Sharma S. Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. Am J Ophthalmol. 2021 05; 225:172-177.

View in: PubMed
Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond). 2020 06; 34(6):1008-1009.

View in: PubMed
Mantravadi S, Ogdie A, Kraft WK. Tumor necrosis factor inhibitors in psoriatic arthritis. Expert Rev Clin Pharmacol. 2017 Aug; 10(8):899-910.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement